Announcements Trials
Browse Landscape

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 7Gynecologic 3Breast 3Other hematologic neoplasm 2Head & Neck 2Thoracic 1Plasma cell 1Other solid neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Multiple Myeloma 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Rituximab 29Surveys and Questionnaires 25Blood Specimen Collection 17Gene Expression Profiling 15Flow Cytometry 14Polymerase Chain Reaction 13Amplified Fragment Length Polymorphism Analysis 13Microarray Analysis 11Observation 10Interviews as Topic 10Psychiatric Rehabilitation 9Lenalidomide 9Immunohistochemistry 9Cytogenetic Analysis 9obinutuzumab 8Watchful Waiting 8Therapeutics 8ibrutinib 7Drug Therapy 7Cyclophosphamide 7Bendamustine Hydrochloride 7Vincristine 6Prednisone 6Magnetic Resonance Spectroscopy 6fludarabine 5In Situ Hybridization, Fluorescence 5Immunologic Techniques 5Data Collection 5Biopsy 5zanubrutinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Mass Screening × Lymphoid × Clear all
NCT05844033 2026-05-19

Biomarker for Infection Risk in CLL and MM

Massachusetts General Hospital

Active not recruiting
150 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡